Back
MaxLinear, Inc. 10K Form
Buy
58
MXL
MaxLinear, Inc.
Last Price:
$17.79
Seasonality Move:
1.1%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-24 | 10Q | MXL/MaxLinear, Inc. Quarterly |
| 2024-01-31 | 10K | MXL/MaxLinear, Inc. Annual |
| 2023-10-25 | 10Q | MXL/MaxLinear, Inc. Quarterly |
| 2023-07-27 | 10Q | MXL/MaxLinear, Inc. Quarterly |
| 2023-04-26 | 10Q | MXL/MaxLinear, Inc. Quarterly |
| 2023-02-01 | 10K | MXL/MaxLinear, Inc. Annual |
Receive MXL News And Ratings
See the #1 stock for the next 7 days that we like better than MXL
MXL Financial Statistics
Sales & Book Value
| Annual Sales: | $360.5M |
|---|---|
| Cash Flow: | $3.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $5.32 |
| Price / Book: | 3.39 |
Profitability
| EPS (TTM): | -2.09620 |
|---|---|
| Net Income (TTM): | $-179.6M |
| Gross Margin: | $192.4M |
| Return on Equity: | -35.65% |
| Return on Assets: | -20.94% |
MaxLinear, Inc. Earnings Forecast
Key MaxLinear, Inc. Financial Ratios
-
The Gross Profit Margin over the past 18 years for MXL is 53.37%.
-
The Selling, General & Administrative Expenses for MXL have been equal to 38.37% of Gross Profit Margin.
-
The Research & Development expenses have been 62.46% of Revenue.
-
The Net Earning history of MXL is -68.01% of Total Revenues.
-
Per Share Earnings over the last 18 years have been positive in 10 years.
MaxLinear, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Semiconductors & Semiconductor Equipment |
| Sector: | Information Technology |
| Current Symbol: | MXL |
| CUSIP: | 57776J |
| Website: | maxlinear.com |
Debt
| Debt-to-Equity Ratio: | 0.31 |
|---|---|
| Current Ratio: | 1.55 |
| Quick Ratio: | 0.91 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 24.11 |
MXL Technical Analysis vs Fundamental Analysis
Buy
58
MaxLinear, Inc. (MXL)
is a Buy
Is MaxLinear, Inc. a Buy or a Sell?
-
MaxLinear, Inc. stock is rated a BuyThe current MaxLinear, Inc. [MXL] share price is $18.05. The Score for MXL is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.